최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Cell death & disease, v.10 no.2, 2019년, pp.85 -
Vigo, Tiziana (IRCCS Ospedale Policlinico San Martino, Genoa, Italy) , La Rocca, Claudia (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Faicchia, Deriggio (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Procaccini, Claudio (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Ruggieri, Maddalena (Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy) , Salvetti, Marco (Centre for Experimental Neurological Therapies (CENTERS), Sapienza University, Rome, Italy) , Centonze, Diego (IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy) , Matarese, Giuseppe (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Uccelli, Antonio (IRCCS Ospedale Policlinico San Martino, Genoa, Italy)
Administration of mesenchymal stem cells (MSC) ameliorate experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), at both clinical and neuropathological levels. The therapeutic properties of MSC in EAE are mainly mediated by the modulation of pathogenic immune resp...
1. Horwitz EM Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement Cytotherapy 2005 7 393 395 10.1080/14653240500319234 16236628
2. Uccelli A Moretta L Pistoia V Mesenchymal stem cells in health and disease Nat. Rev. Immunol. 2008 8 726 736 10.1038/nri2395 19172693
3. Uccelli A Laroni A Freedman MS Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases Lancet Neurol. 2011 10 649 656 10.1016/S1474-4422(11)70121-1 21683930
4. Bai L Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis Glia 2009 57 1192 1203 10.1002/glia.20841 19191336
5. Gerdoni E Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis Ann. Neurol. 2007 61 219 227 10.1002/ana.21076 17387730
6. Gordon D Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration Neurosci. Lett. 2008 448 71 73 10.1016/j.neulet.2008.10.040 18950680
7. Rafei, M. et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182 , 5994?6002 (2009).
8. Zappia E Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy Blood 2005 106 1755 1761 10.1182/blood-2005-04-1496 15905186
9. Zhang J Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice Exp. Neurol. 2005 195 16 26 10.1016/j.expneurol.2005.03.018 15904921
10. Ren G Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide Cell Stem Cell 2008 2 141 150 10.1016/j.stem.2007.11.014 18371435
11. Vigo T IFN-gamma orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways J. Allergy Clin. Immunol. 2017 139 1667 1676 10.1016/j.jaci.2016.09.004 27670240
12. Bai L Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models Nat. Neurosci. 2012 15 862 870 10.1038/nn.3109 22610068
13. Connick P Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study Lancet Neurol. 2012 11 150 156 10.1016/S1474-4422(11)70305-2 22236384
14. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352 , 1498?1504 (1998)..
15. Platanias LC Fish EN Signaling pathways activated by interferons Exp. Hematol. 1999 27 1583 1592 10.1016/S0301-472X(99)00109-5 10560905
16. Severa M Rizzo F Giacomini E Salvetti M Coccia EM IFN-beta and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks Cytokine Growth Factor Rev. 2015 26 229 239 10.1016/j.cytogfr.2014.11.005 25498525
17. Severa M IFN-beta therapy regulates TLR7-mediated response in plasmacytoid dendritic cells of multiple sclerosis patients influencing an anti-inflammatory status J. Interferon Cytokine Res. 2015 35 668 681 10.1089/jir.2014.0207 25923141
18. Alenda R Blood lymphocyte subsets identify optimal responders to IFN-beta in MS 2018 265 24 31
19. Vandenbark AA Interferon-beta-1a treatment increases CD56 bright natural killer cells and CD4+CD25+Foxp3 expression in subjects with multiple sclerosis J. Neuroimmunol. 2009 215 125 128 10.1016/j.jneuroim.2009.08.007 19758707
20. Majchrzak-Gorecka, M., Majewski, P., Grygier, B., Murzyn, K. & Cichy, J. Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response. Cytokine Growth Factor Rev . 10.1016/j.cytogfr.2015.12.001 (2015).
21. De Rosa V A key role of leptin in the control of regulatory T cell proliferation Immunity 2007 26 241 255 10.1016/j.immuni.2007.01.011 17307705
22. Kasper LH Reder AT Immunomodulatory activity of interferon-beta Ann. Clin. Transl. Neurol. 2014 1 622 631 10.1002/acn3.84 25356432
23. Croitoru-Lamoury J Lamoury FM Zaunders JJ Veas LA Brew BJ Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone J. Interferon Cytokine Res. 2007 27 53 64 10.1089/jir.2006.0037 17266444
24. Taggart CC Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding J. Exp. Med. 2005 202 1659 1668 10.1084/jem.20050768 16352738
25. Guerrieri D Serine leucocyte proteinase inhibitor-treated monocyte inhibits human CD4(+) lymphocyte proliferation Immunology 2011 133 434 441 10.1111/j.1365-2567.2011.03451.x 21574992
26. Tateosian NL Neutrophil elastase treated dendritic cells promote the generation of CD4(+)FOXP3(+) regulatory T cells in vitro Cell Immunol. 2011 269 128 134 10.1016/j.cellimm.2011.03.013 21477798
27. Mueller AM Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis J. Neuroinflamm. 2008 5 20 10.1186/1742-2094-5-20
28. Norata GD The cellular and molecular basis of translational immunometabolism Immunity 2015 43 421 434 10.1016/j.immuni.2015.08.023 26377896
29. Fischer K Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 2007 109 3812 3819 10.1182/blood-2006-07-035972 17255361
30. Dietl K Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes J. Immunol. 2010 184 1200 1209 10.4049/jimmunol.0902584 20026743
31. Marin-Banasco C Gene therapy with mesenchymal stem cells expressing IFN-ss ameliorates neuroinflammation in experimental models of multiple sclerosis Br. J. Pharmacol. 2017 174 238 253 10.1111/bph.13674 27882538
32. Kim MJ Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis J. Neuroimmunol. 2018 314 81 88 10.1016/j.jneuroim.2017.11.010 29224961
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.